Studying the Effects of Cannabis on Vasculature
SECV
Elucidating the Effects of Cannabis on Cardiovascular System
1 other identifier
observational
100
1 country
1
Brief Summary
Cannabis is commonly used globally. It is associated with psychiatric problems, but the effects on the cardiovascular system are unclear. In this project, the investigators plan to study the effects of cannabis on the cardiovascular system. This will be done by using a non-invasive test to measure blood vessel function and by using blood samples to measure inflammation. As a control for this project, the investigators would like to test the blood vessel function and inflammation levels of participants who do not use cannabis. This study will provide important information on the long term cardiovascular effects of cannabis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2023
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 12, 2022
CompletedFirst Posted
Study publicly available on registry
October 14, 2022
CompletedStudy Start
First participant enrolled
December 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2025
CompletedJune 15, 2025
June 1, 2025
1.6 years
October 12, 2022
June 11, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
Inflammation
The investigators will measure the concentration of inflammatory cytokines using an Olink for chronic cannabis users and the control group.
Baseline measurement.
Endothelial function
The investigators will measure the reactive hyperaemia index (RHI) using an EndPAT device for both groups.
Baseline measurement.
Secondary Outcomes (3)
Cholesterol Level
Baseline measurement.
BMI
Baseline measurement.
Blood pressure
Baseline measurement.
Study Arms (2)
Chronic Cannabis Cohort
For investigations on the effects of cannabis on the cardiovascular system, the investigators would like to recruit 50 participants with the following inclusion criteria: * age: 19 to 80 * males and females * all ethnicities * cannabis use at least 3-4 times per week or more in the past 6 months (50 volunteers, experimental group) * no history of cardiovascular disease For investigations on the effects of cannabis on the cardiovascular system, the investigators will exclude cannabis users: * that ingest cannabis containing cannabidiol (CBD) * that are unable to provide a receipt for the cannabis product(s) they ingest * that are unwilling to stop consuming soy products and/or genistein 48 hours prior to appointments.
Control Cohort
For investigations on the effects of cannabis on the cardiovascular system, the investigators would like to recruit 50 participants with the following inclusion criteria: * age: 19 to 80 * males and females * all ethnicities * patients who do not use cannabis * no history of cardiovascular disease For investigations on the effects of cannabis on the cardiovascular system, the investigators will exclude participants: * that ingest cannabis * that are unwilling to stop consuming soy products and/or genistein 48 hours prior to appointments.
Interventions
The investigators will test levels of inflammation and vascular dysfunction in participants who chronically use cannabis.
Eligibility Criteria
The investigators plan to recruit participants from the London Health Sciences Centre HIV clinic and chronic pain clinic who use cannabis for medicinal purposes.
You may qualify if:
- age: 19 to 80
- males and females
- all ethnicities
- cannabis use at least 3-4 times per week or more in the past 6 months (50 volunteers, experimental group)
- patients who do not use cannabis (50 volunteers, control group)
- no history of cardiovascular disease
You may not qualify if:
- that ingest cannabis containing cannabidiol (CBD)
- that are unable to provide a receipt for the cannabis product(s) they ingest
- that are unwilling to stop consuming soy products and/or genistein 48 hours prior to appointments.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
London Regional Health Science Centre
London, Ontario, N6A 5A5, Canada
Biospecimen
The investigators would like to test blood and vascular function of chronic cannabis users for signs of vascular dysfunction. The investigators e will obtain blood from a single blood draw using EDTA tubes. The investigators will separate into plasma, red blood cells, and white blood cells. The investigators will test the plasma from control and chronic cannabis users with a lipid panel, complete metabolic panel, HgbA1c, fasting glucose, and Olink inflammation panel. The investigators will retain unused plasma and peripheral blood mononuclear cells for future studies.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
October 12, 2022
First Posted
October 14, 2022
Study Start
December 1, 2023
Primary Completion
June 30, 2025
Study Completion
December 30, 2025
Last Updated
June 15, 2025
Record last verified: 2025-06